Christopher Bowlus

2025

• Long-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.

  Levy C, Trivedi P, Kowdley K, Gordon S, Bowlus C, Londoño M, Hirschfield G, Gulamhusein A, Lawitz E, Vierling J, Mayo M, Jacobson I, Kremer A, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter C, Crittenden D. Long-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. The American Journal Of Gastroenterology 2025 PMID: 40553148, DOI: 10.14309/ajg.0000000000003603.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis

  Caines A, Lu M, Wu T, Trudeau S, Melkonian C, Gonzalez H, Sahota A, Schmidt M, Daida Y, Bowlus C, Gordon S. Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. Journal Of Gastroenterology And Hepatology 2025 PMID: 40551359, DOI: 10.1111/jgh.17035.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• P197 Long-term efficacy and safety of open-label seladelpar in primary biliary cholangitis: pooled interim results up to 3 years from ASSURE

  Lawitz E, Trivedi P, Kowdley K, Gordon S, Bowlus C, Londoño M, Hirschfield G, Gulamhusein A, Crittenden D, Zhuo S, Heusner C, Levy C. P197 Long-term efficacy and safety of open-label seladelpar in primary biliary cholangitis: pooled interim results up to 3 years from ASSURE. 2025, a205-a205. DOI: 10.1136/gutjnl-2025-bsg.332.

  Peer-Reviewed Original Research

  Concepts

• P200 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated cirrhosis in the phase 3 RESPONSE trial

  Villamil A, Younes Z, Bowlus C, Vierling J, Vasura A, Galli A, Rabinovitz M, Nevens F, Carroll S, Yang K, Crittenden D, McWherter C, Lawitz E. P200 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated cirrhosis in the phase 3 RESPONSE trial. 2025, a207-a208. DOI: 10.1136/gutjnl-2025-bsg.335.

  Peer-Reviewed Original Research

  Concepts

• P201 Impact of elafibranor on markers of disease activity and progression in patients with advanced primary biliary cholangitis

  Phagura A, Mayo M, Kowdley K, Bowlus C, Vierling J, Jacobson I, Antunes N, Sleiman M, Touati N, Zein C, Levy C. P201 Impact of elafibranor on markers of disease activity and progression in patients with advanced primary biliary cholangitis. 2025, a208-a209. DOI: 10.1136/gutjnl-2025-bsg.336.

  Peer-Reviewed Original Research

  Concepts

• P203 Attenuation, near resolution, and prevention of pruritus in patients with primary biliary cholangitis receiving seladelpar: a secondary analysis from RESPONSE

  Kremer A, Levy C, Mayo M, Bowlus C, Kowdley K, Hirschfield G, Carroll S, Yang K, Crittenden D, McWherter C. P203 Attenuation, near resolution, and prevention of pruritus in patients with primary biliary cholangitis receiving seladelpar: a secondary analysis from RESPONSE. 2025, a209-a209. DOI: 10.1136/gutjnl-2025-bsg.337.

  Peer-Reviewed Original Research

  Concepts

• P232 Long-term safety of seladelpar 10 mg with up to 5 years of treatment in patients with primary biliary cholangitis

  Trivedi P, Gordon S, Gulamhusein A, Villamil A, Lawitz E, Vierling J, Londoño M, Kremer A, Bowlus C, Proehl S, Zhuo S, Crittenden D, McWherter C. P232 Long-term safety of seladelpar 10 mg with up to 5 years of treatment in patients with primary biliary cholangitis. 2025, a228-a228. DOI: 10.1136/gutjnl-2025-bsg.366.

  Peer-Reviewed Original Research

  Concepts

• P250 Beyond the mean: exploring the impact of baseline alkaline phosphatase levels on endpoints in primary biliary cholangitis

  Tranter L, Levy C, Bowlus C, Lawitz E, Antunes N, Miller B, Shu J, Zein C, Kowdley K. P250 Beyond the mean: exploring the impact of baseline alkaline phosphatase levels on endpoints in primary biliary cholangitis. 2025, a239.2-a241. DOI: 10.1136/gutjnl-2025-bsg.384.

  Peer-Reviewed Original Research

• FP7 Bexotegrast improves markers and symptoms of cholestasis and stabilizes markers of liver fibrosis in participants with primary sclerosing cholangitis

  Trivedi P, Kowdley K, Eksteen B, Hameed B, Vincent C, Chen T, Goel A, Reddy G, Orman E, Joshi D, Lefebvre É, Barnes C, Pencek R, Thorburn D, Montano-Loza A, Schramm C, Bowlus C, Trauner M, Levy C, Hirschfield G. FP7 Bexotegrast improves markers and symptoms of cholestasis and stabilizes markers of liver fibrosis in participants with primary sclerosing cholangitis. 2025, a59.2-a60. DOI: 10.1136/gutjnl-2025-bsg.90.

  Peer-Reviewed Original Research

  Concepts

• Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry

  Dean R, Yazdanfar M, Zepeda J, Levy C, Lammert C, Pratt D, Gordon S, Forman L, Assis D, McGirr A, McLaughlin M, Mukherjee S, Gungabissoon U, Bowlus C. Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry. Hepatology Communications 2025, 9: e0703. PMID: 40366147, PMCID: PMC12055165, DOI: 10.1097/hc9.0000000000000703.

  Peer-Reviewed Original Research

  MeSH Keywords and Concepts